Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.
Lancet
; 396(10255): 887-897, 2020 09 26.
Article
in En
| MEDLINE
| ID: mdl-32896291
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Viral Vaccines
/
Immunization, Secondary
/
Coronavirus Infections
/
Pandemics
Type of study:
Clinical_trials
Limits:
Adult
/
Female
/
Humans
/
Male
Country/Region as subject:
Asia
/
Europa
Language:
En
Journal:
Lancet
Year:
2020
Document type:
Article
Country of publication: